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Abstract
Background: Reasons for attrition in studies vary, but may be a major concern in long-term
studies if those who drop out differ systematically from those who continue to participate. Factors
associated with dropout were evaluated in a twelve-year community-based, prospective cohort
study of urologic disease in men.
Methods: During 1989–1991, 2,115 randomly selected Caucasian men, ages 40–79 years from
Olmsted County, Minnesota were enrolled and followed with questionnaires biennially; 332 men
were added in follow-up. A random subset (~25%) received a urologic examination. Baseline
characteristics including age, benign prostatic hyperplasia (BPH) symptoms, comorbidities, and
socioeconomic factors were compared between subjects who did and did not participate after the
twelfth year of follow-up.
Results: Of the 2,447 men, 195 died and were excluded; 682 did not participate in 2002.
Compared with men in the 40–49 year age group, men ≥ 70 years of age at baseline had a greater
relative odds of dropout, 2.65 (95% CI: 1.93, 3.63). In age-adjusted analyses, relative to men without
stroke, men who had suffered a stroke had a higher odds of dropout, age-adjusted OR 3.07 (95%
CI: 1.49, 6.33). Presence of at least one BPH symptom was not associated with dropout, (age-
adjusted OR 1.12 (95% CI: 0.93, 1.36)).
Conclusion: These results provide assurance that dropout was not related to primary study
outcomes. However, factors associated with dropout should be taken into account in analyses
where they may be potential confounders.
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Attrition becomes a major concern in long-term studies if
those who drop out differ systematically from those who
continue to participate. Common statistical methods used
for cohort studies assume there is no difference between
subjects who drop out of the study and those who con-
tinue to participate. However, if this assumption is false,
the validity of the study may be jeopardized and the dif-
ference between the observed values and "true" values
may increase with study follow-up [1]. This is of particular
concern if disease severity influences study participation.
Losses in long-term studies may be due to refusals to con-
tinue in a study, inability to trace individuals for follow-
up, and deaths.
Few studies of urologic conditions, such as benign pros-
tatic hyperplasia (BPH), have examined dropout of study
participants over the long term. One prospective cohort
study of urinary symptoms followed participants for up to
four years, and documented a dropout rate of 29%. Men
with the highest levels of lower urinary tract symptom
bother and interference at baseline, dropped out by last
year of follow-up [2]. Two long-term, double-blind clini-
cal trials which evaluated urologic outcomes, the Medical
Therapy of Prostatic Symptoms (MTOPS) trial [3] and the
Proscar Long-term Efficacy and Safety Study (PLESS) [4],
evaluated dropout. In the MTOPS study the rate of loss
was 2.5 per 100 patient-years in the placebo group and
ranged from 2.2 to 3.3 in the treatment groups [3]. By the
end of the PLESS study, 42% of patients had discontinued
treatment. However, follow-up data were available on
92% of the randomized patients, but differences in men
who dropped out compared with those who continued to
participate were not examined [5]. Roehrborn [6] exam-
ined the importance of patient follow-up after discontin-
uation and concluded that in order to compare the true
event rate across clinical trials, discontinuation rates and
total patient follow-up for clinical outcomes must be
assessed, a recommendation that is applicable to cohort
studies as well.
The Olmsted County Study of Urinary Symptoms and
Health Status among Men is a community-based, pro-
spective cohort study that offers an ideal opportunity to
identify characteristics associated with dropout, and to
determine if these factors might bias results from this
study.
Methods
Study design and population
The Olmsted County Study of Urinary Symptoms and
Health Status among Men was initiated in December
1989 and details have been published elsewhere [7-9].
Briefly, this study is a community-based, prospective
cohort study of Caucasian men who were 40–79 years of
age on January 1, 1990, randomly selected from the Olm-
sted County, Minnesota population. The goal of the study
was to determine the natural history of urinary symptoms
and BPH. Potential subjects were identified through the
Rochester Epidemiology Project [10]. Community medi-
cal records of all the randomly selected men were
reviewed for history of prostate cancer, prostatectomy,
and other medical conditions which may impede normal
voiding function, such as neurologic disease, lower back
surgery and urethral stricture. After exclusion for these
pre-existing conditions and/or treatments, 3,874 men
were asked to join the study and of these 2,115 agreed to
participate (55% participation rate).
Data collection
Individual participants were visited in their homes, signed
informed consent documentation, and were asked to
complete a questionnaire which documented demo-
graphic information, including the participant's age, mar-
ital status, education level, and annual salary. The
questionnaire also assessed lower urinary tract symptom
severity with questions similar to the American Urological
Association Symptom Index (AUASI) [11-13]. Urinary
bother and interference with daily activities were assessed
using a Health-Related Quality of Life (HRQL) question-
naire specific for BPH [14]. Information on the presence
of comorbidities and other urologic conditions, including
erectile dysfunction (ED), diabetes mellitus, stroke, heart
disease, and hypertension were reported on the baseline
questionnaire. In addition, men voided into a portable
uroflow meter (Dantec 1000) to assess lower urinary func-
tion.
A 25% random sub-sample of the study cohort, 475 out
of 537 men (88%), agreed to participate in a detailed clin-
ical urologic examination, including serum prostate spe-
cific antigen (PSA) level, digital rectal examination, and
transrectal sonographic imaging of the prostate to deter-
mine prostatic volume. Measurements were made of the
anteroposterior, transverse, and superoinferior diameters
and prostate volume was estimated using the formula for
a prolate ellipsoid, π/6 (transverse × anteroposterior × super-
oinferior) [15]. All study procedures were approved by the
Mayo Foundation Institutional Review Board (IRB).
The cohort has been actively followed biennially, with a
similar protocol to the initial examination. In follow-up,
questionnaires were mailed to participants rather than
completed at in-home visits. Our study developed
detailed algorithms regarding contact procedures for
study participants (Figure 1). Initially, clinic registration
and vital status were reviewed. Men who had died or who
withdrew from the study in writing were removed from
the contact list. However, we examined possible bias due
to death by including deaths between contacts as drop-Page 2 of 8
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the study with a list of study publications, and question-
naires were mailed to study participants on a biennial
basis using a 30-day contact interval for non-responders.
If participants failed to respond after the third mailing,
study personnel attempted to reach them via phone. If
contact was not initiated after five phone calls, no further
contact was attempted for that round. Any participant
could elect not to participate in the study at any time with-
out any negative impact on their medical care at the clinic.
Men who were diagnosed with prostate cancer, received a
radical prostatectomy, or transurethral resection of the
prostate (TURP) were not excluded from the cohort, but
were excluded from participating in the detailed urologic
examination. During the second and third biennial fol-
low-up, men who did not participate in the follow-up
were replaced by men randomly selected from the com-
munity, after being screened for the exclusion criteria used
at baseline (n = 229 and n = 103, respectively). Of the
replacement men, randomly selected individuals were
added to the clinic sub-sample in the years two and four
of follow-up, (n = 100 and n = 58, respectively). Since that
time the study has been maintained as a closed cohort. At
the twelfth year of follow-up, 682 (30.3% of live enroll-
ees) men had dropped out of the study.
Statistical analysis
Baseline urologic health status, comorbidities, HRQL, and
socioeconomic status were compared among the men
who dropped out and those who continued to participate
in the twelfth year of follow-up of the study. Men who
died between contacts (n = 195) were removed from the
analysis, including 46 men in the clinic subset. An alpha
of p < 0.05 was considered statistically significant.
Urologic measures were dichotomized according to stand-
ard cut points. Urinary symptoms were assessed by the
AUASI. Scores ranged from 0 (none) to 35 (severe), with
scores from 8 to 19 classified as "moderate" symptoms
and scores ≥ 20 classified as "severe" symptoms. These
two categories were combined in the analyses, and scores
> 7 were considered moderate/severe symptoms [16].
Other urinary outcomes evaluated were peak urinary flow
rate (< 12 ml/second) [17], prostate volume (> 30 cm3)
[17], serum PSA level (> 1.4 ng/mL, upper 25th percentile
for this cohort at baseline), and creatinine (> 1.4 ng/dL)
[18]. A chi-square test was used to compare the distribu-
tion of urologic measures among participants and those
who dropped out.
Logistic regression was used to calculate age-adjusted
odds ratios (OR) comparing individuals who dropped out
and those who continued to participate in the twelfth year
of follow-up of the study. A multivariable model was con-
structed to simultaneously adjust for age, urologic health
status, comorbidities, HRQL, and socioeconomic factors
in predicting dropout from the study. This model con-
tained the variable with the strongest age-adjusted associ-
ation from each domain. Forward selection logistic
regression verified the final model. All 2-way interactions
between variables were also evaluated. To account for
multiple comparisons in these models a p-value of 0.005
was used for inclusion-exclusion in the model. All analy-
ses were conducted using SAS, version 8.2 (SAS Institute,
Cary, N.C.)
Results
In univariate analyses, we found that older men were
more likely to drop out of our study compared to younger
men (Table 1). Although men who were 70 years or older
at baseline made up the smallest number of participants
in the total cohort, this group had the largest dropout.
Furthermore, men who dropped out were more likely to
have moderate/severe symptoms and decreased urinary
flow rates compared to those who remained in the study
(Table 1). The presence of an enlarged prostate and ele-
vated PSA did not differ significantly between men who
participated and those who dropped out.
We next adjusted for age and determined whether other
specific participant characteristics were associated with
dropping out of our study (Table 2). Clinical urologic
measures were not strongly associated with increased
dropout. Men who reported they had ever suffered a
stroke were over three times more likely to drop out com-
pared to men who had not suffered a stroke (Table 2).
However, this represented a small percentage of the
cohort, with only 22 men who suffered a stroke dropping
out. Men with any comorbidity present were more likely
to drop out of the study than men without any comorbid-
ity. Other factors that were significantly associated with
study dropout included presence of ED and dissatisfaction
with their urinary condition or overall health. Men who
were satisfied with their urinary condition and overall
health were less likely to drop out (Table 2). In addition,
men who had more interference with living activities from
their urinary problems were more likely to drop out than
those men with less interference. Lower socioeconomic
status was also associated with study dropout. Men who
had a high school education were less likely to drop out of
the study compared to men without at least a high school
education (Table 2). Men reporting higher salaries were
also less likely to drop out of the study. Finally, men who
were randomly selected to participate in the clinic subset
were less likely to drop out than men who were not.
When considered simultaneously in a multivariable
model, older men with poor health status were more
likely to dropout; however the magnitude of the associa-Page 3 of 8
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life score, more education and participation in the clinic
subset were more likely to remain in the study (Table 3).
Discussion
Our results suggest several factors that may help predict
which men are more likely to drop out versus continue to
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ical finding however, is that, after adjusting for age, there
were no differences in primary study outcomes at baseline
between individuals who dropped out and those who
continued to participate in the twelfth year of follow-up.
Our findings showed that men with ED were more likely
to drop out of the study compared to those without ED. It
is possible that this condition may have been too frustrat-
ing for the men to continue to participate in the study or
initially they may have perceived a potential benefit for
this condition by participating in the study. Alternatively,
as ED is associated with several comorbidities and life-
style factors, i.e. smoking, diabetes, cardiovascular disease
[19,20], drop out associated with ED may be related to
other health issues.
Our results show that older men with poorer general
health status were more likely to drop out of the study.
The increased dropout in older men with comorbid con-
ditions is consistent with other studies [21-23], where
nonresponse bias in the older subset was a concern.
Therefore, additional efforts may be required to encour-
age older participants and those with co-morbid condi-
tions to continue participation in long-term studies. In
addition, this demonstrates the need for assessing the
effects of age stratification and age-adjustment when eval-
uating study outcome variables. Furthermore, comorbidi-
ties may be confounded with age, as the risk for comorbid
conditions tends to increase with age [21-23].
Health-related quality of life measures also showed that
men who suffered more interference from their urologic
symptoms were more likely to drop out than men with
less interference. This is consistent with a five-year natural
history study of BPH in Scotland [2] in which men who
reported having the highest levels of bother and interfer-
ence at baseline were less likely to participate in the survey
at 5 years. It was proposed that one reason for this was
that men may adjust to their symptoms over time and
adapt their life-style to accommodate symptoms. Alterna-
tively, these men may not have seen any personal benefit
to continued participation in the study.
Men with a lower socioeconomic status were also more
likely to drop out of the study. Although few urologic
studies have documented the effect of education level on
study dropout, numerous studies of other disease condi-
tions have documented the potential effect of education
level on study attrition. For example, in a longitudinal,
multicenter AIDS cohort study examining retention after
Table 1: Characteristics of men who participated versus those who dropped out of The Olmsted County Study of Urinary Symptoms 
and Health Status among Men, Rochester, Minnesota (1989–2003)
Baseline Questionnaire†
Participated Dropped out‡
No. % No. % Chi-sq p
AGE (years)
40–49 734 46.7 336 49.3 0.01
50–59 458 29.2 138 20.2
60–69 293 18.7 105 15.4
70+ 85 5.4 103 15.1
AUASI*
≤ 7 1105 70.4 452 66.3 0.05
> 7 465 29.6 230 33.7
QMAX (mL/s)*
≥ 12 1297 82.8 532 78.2 0.01
< 12 269 17.2 148 21.8
PSA (ng/mL)*
≤ 1.4 329 75.3 107 70.9 0.28
> 1.4 108 24.7 44 29.1
VOL (cm3)*
≤ 30 300 68.8 94 62.7 0.17
> 30 136 31.2 56 37.3
* AUASI, American Urological Association Symptom Index; QMAX, peak urinary flow rate; PSA, Prostate-Specific Antigen; VOL, prostate volume.
† Age was calculated based on the age at baseline questionnaire completion.
‡ No questionnaire completed in seventh biennial contact year.
§ Men who died between contacts were excluded, n = 195.
¶ Of the 195 excluded men, 46 were men in the clinic subset.
# PSA and VOL measurements are from the randomly selected in-clinic subset, n = 588.Page 5 of 8
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ated with nonparticipation [24]. In addition, a study
examining predictors of inactivation and reasons for par-
ticipant inactivation during skin cancer chemoprevention
found that a low education level was a significant predic-
tor of inactivation [25]. One explanation for this finding
is that men with a lower education level may not fully
appreciate the benefits of study participation. An
approach to this issue may be to offer educational semi-
nars or orientation sessions for study subjects that outline
and discuss the benefits participants and society may
receive from the study.
In our study, with the approval of the Mayo IRB, we have
used a combination of active and passive follow-up to
assess characteristics associated with participant dropout.
This has allowed us to gauge the probability and degree of
study bias due to nonparticipation. This level of follow-up
is unique, and may not be feasible for other studies, as few
studies have access to medical records for both partici-
pants and nonparticipants. However, our study may have
greater validity for the target study population, due to our
ability to assess not only participants, but also those sub-
jects who have previously dropped out of the study.
There are some limitations to the generalizability of this
study. All participants in the Olmsted County Study of
Urinary Symptoms and Health Status among Men are
Caucasian and were 40–79 years of age at study entry.
Therefore, the ability to generalize these findings to other
ethnic populations and age groups may be limited. We
excluded men who died between contacts. By doing this,
we assumed that death was unrelated to our outcome.
However, the men who died may have been in poorer
health and may have been at greater risk for clinical uro-
logic conditions. We repeated our initial analysis includ-
Table 2: Age-adjusted comparisons of relative odds of dropping out of The Olmsted County Study of Urinary Symptoms and Health 
Status among Men based on baseline measurements, Rochester, Minnesota (1989–2003)
Primary Study Outcomes Age-adjusted OR* (95% CI*)
AUASI* (> 7 vs. ≤ 7) 1.19 (0.97, 1.45)
Peak Urinary Flow Rate (QMAX) (< 12 vs. ≥ 12 mL/s) 1.18 (0.93, 1.50)
Prostate Volume (> 30 vs. ≤ 30 cm3) 0.98 (0.62, 1.56)
Prostate-Specific Antigen (> 1.4 vs. ≤ 1.4 ng/mL) 0.90 (0.55, 1.46)
Any Benign Prostatic Hyperplasia (Yes vs. No) 1.12 (0.93, 1.36)
Member of Clinic Subset (Yes vs. No) 0.73 (0.59, 0.90)
Comorbidities
Diabetes (Yes vs. No) 1.24 (0.77, 1.99)
Stroke (Yes vs. No) 3.07 (1.49, 6.33)
Hypertension (Yes vs. No) 1.23 (0.97, 1.56)
Coronary Disease (Yes vs. No) 1.25 (0.92, 1.68)
Any Comorbidity (Yes vs. No) 1.31 (1.06, 1.61)
Other Urologic Measures
Creatinine (> 1.4 vs. ≤ 1.4 ng/dL) 1.10 (0.45, 2.66)
Erectile Dysfunction (Yes vs. No) 1.69 (1.26, 2.28)
Quality of Life Measures
Satisfied with Urinary Condition (Yes vs. No) 0.65 (0.49, 0.87)
Satisfied with overall health/HRQL* (Yes vs. No) 0.29 (0.19, 0.43)
Visited a doctor more than 4 times in the past 12 months (Yes vs. No) 1.30 (0.96, 1.75)
Interference Score (> 9 vs. ≤ 9) 1.32 (1.07, 1.62)
Socioeconomic Measures
High School Graduate or More (Yes vs. No) 0.40 (0.29, 0.56)
Married or Living Together (Yes vs. No) 0.81 (0.60, 1.08)
Salary ($15,000–$34,999 vs. ≤ $14,999/year) 0.65 (0.48, 0.90)
Salary (≥ $35,000 vs. ≤ $14,999/year) 0.44 (0.33, 0.60)
* OR, Odds Ratio; CI, Confidence Interval; AUASI, American Urological Association Symptom Index; HRQL, Health-Related Quality of Life.Page 6 of 8
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were similar (data not shown). Moreover, nonparticipa-
tion, per se, was not related to primary study outcomes at
baseline (after adjusting for age).
Another potential limitation was the 55% participation
rate; however, factors associated with participation may
not be the same factors associated with dropout. We have
previously documented differences in the characteristics
of baseline participants and nonparticipants in age, home
location, and prior history of urologic conditions [26].
The age-adjusted period prevalence rate for benign pros-
tatic hyperplasia was 9.6% (95% CI: 8.1, 11.0) for full par-
ticipants, 8.2% (95% CI: 5.8, 10.6) for partial participants
and 5.3% (95% CI: 3.6, 6.9) for complete non-respond-
ers. These results suggest that initial participation in our
study may have been at least partially driven by concerns
about urologic health. No differences were found between
participants and nonparticipants in other major medical
comorbidities. Additionally, longitudinal assessment of
the cohort did not show any differences in urologic out-
comes identified through medical record abstraction
between participants and nonparticipants [27]. Therefore,
while it is possible that some of the men who did not ini-
tially participate in our study might have been more likely
to drop out, an earlier study of these groups did not sug-
gest that initial nonparticipants differed dramatically
from participants.
Conclusion
Regardless of these limitations, this study demonstrates
that cohort studies may encounter differential attrition
associated with poor health status, increasing age, lower
education level and socioeconomic status. Even well
designed cohort studies and clinical trials will suffer if dif-
ferential attrition biases results. Thorough planning, spe-
cial efforts to encourage continued participation and
statistical methods can be implemented to minimize
dropout and correct for non-response bias. Differential
attrition in this study did not bias our primary study out-
comes, however future reports from this and other uro-
logic studies which focus on ED will need to address the
degree to which dropout might bias those results.
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